Teased last month at the annual J.P. Morgan Healthcare Conference, Teva’s new CEO Richard Francis has confirmed that a full strategic review is now underway, which will look to answer “some of the core strategic questions, and how the segments we operate in are going to evolve over time.”
Teva Promises New Strategy By The Summer, Washes Hands Of $1bn US Target
Strategic Review Will Consider ‘How Business Segments Evolve Over Time’
Still only six weeks into the job, Teva’s new CEO Richard Francis and his senior team are busy working on a refreshed company strategy, as Teva looks to grow its top line in 2023 for the first time in six years.
